‪Kostapanos Michael, MD, PhD, DHP, FRCP, FRSPH‬

Cited by

	All	Since 2019
Citations	4496	1234
h-index	33	17
i10-index	71	37

520

260

130

390

20072008200920102011201220132014201520162017201820192020202120222023202418 75 101 133 180 254 429 512 428 390 313 273 226 232 237 246 207 82

Public access

View all

12 articles

1 article

available

not available

Based on funding mandates

Co-authors

Haralampos MilionisProfessor of Internal Medicine, University of IoanninaVerified email at uoi.gr
Evangelos LiberopoulosNational and Kapodistrian University of AthensVerified email at med.uoa.gr
Filippatos TheodosiosAssociate Professor of Internal Medicine, Department of Internal Medicine, School of MedicineVerified email at uoc.gr
Evangelos C. RizosConsultant in Internal Medicine, Diabetologist, University Hospital of Ioannina, Ioannina, GreeceVerified email at external.euc.ac.cy
Bairaktari EleniVerified email at uoi.gr
Evangelia Ntzani, MD, PhDUniversity of Ioannina School of Medicine; CESH, Brown University School of Public HealthVerified email at cc.uoi.gr
Joseph CheriyanCambridge University Hospitals NHS TrustVerified email at cam.ac.uk
Aris P AgouridisAssistant Professor of Internal Medicine/Pathophysiology, School of Medicine, European UniversityVerified email at euc.ac.cy
Vasilis TsimihodimosUniversity of IoanninaVerified email at uoi.gr
George LiamisProfessor of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, GreeceVerified email at uoi.gr
Fotios BarkasDepartment of Internal Medicine, Faculty of Medicine, University of Ioannina, GreeceVerified email at cc.uoi.gr
Simon BondCambridge Clinical Trials Unit, MRC Biostatistics UnitVerified email at addenbrookes.nhs.uk
Petros SkapinakisUniversity of IoanninaVerified email at cc.uoi.gr
Athyros VEmeritus Professor of Internal Medicine Aristotelian University, Thessaloniki, GreeceVerified email at med.auth.gr
Tellis CUniversity of IoanninaVerified email at cc.uoi.gr
Christina-Maria KastoriniPhD cand.Verified email at hua.gr
Demosthenes PanagiotakosProfessor at Harokopio University in AthensVerified email at hua.gr
thanos athanasiouprofessor of cardiovascular sciences and cardiac surgeryVerified email at imperial.ac.uk
Petros TzimasProfessor of AnaesthesiologyVerified email at uoi.gr
Anna Challaassociate professor of medicine, Univ of IoanninaVerified email at uoi.gr

Kostapanos Michael, MD, PhD, DHP, FRCP, FRSPH

Consultant Physician and Affiliated Assistant Professor, Cambridge University Hospitals and

Verified email at cam.ac.uk

Clinical Pharmacology Lipids Hypertension Cardiovascular disease prevention Diabetes


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis EC Rizos, EE Ntzani, E Bika, MS Kostapanos, MS Elisaf Jama 308 (10), 1024-1033, 2012	1374	2012
Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A₂ VG Saougos, AP Tambaki, M Kalogirou, M Kostapanos, IF Gazi, ... Arteriosclerosis, thrombosis, and vascular biology 27 (10), 2236-2243, 2007	176	2007
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia MS Kostapanos, HJ Milionis, MS Elisaf American journal of cardiovascular drugs 10, 11-28, 2010	156	2010
An overview of the extra-lipid effects of rosuvastatin MS Kostapanos, HJ Milionis, MS Elisaf Journal of cardiovascular pharmacology and therapeutics 13 (3), 157-174, 2008	128	2008
Do statins have an antiarrhythmic activity? MS Kostapanos, EN Liberopoulos, JA Goudevenos, DP Mikhailidis, ... Cardiovascular research 75 (1), 10-20, 2007	126	2007
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease MS Kostapanos, A Kei, MS Elisaf World journal of hepatology 5 (9), 470, 2013	113	2013
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) HJ Milionis, E Rizos, M Kostapanos, TD Filippatos, IF Gazi, ES Ganotakis, ... Current medical research and opinion 22 (6), 1123-1131, 2006	105	2006
Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind … TX Zhao, M Kostapanos, C Griffiths, EL Arbon, A Hubsch, F Kaloyirou, ... BMJ open 8 (9), e022452, 2018	98	2018
Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance E Moutzouri, E Liberopoulos, DP Mikhailidis, MS Kostapanos, AA Kei, ... International journal of clinical practice 65 (11), 1141-1148, 2011	95	2011
Do statins beneficially or adversely affect glucose homeostasis? M S Kostapanos, G L Liamis, H J Milionis, M S Elisaf Current vascular pharmacology 8 (5), 612-631, 2010	94	2010
Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and … CV Rizos, HJ Milionis, MS Kostapanos, M Florentin, CE Kostara, ... Clinical therapeutics 32 (3), 492-505, 2010	75	2010
The impact of the metabolic syndrome on health-related quality of life: a cross-sectional study in Greece D Tziallas, C Kastanioti, MS Kostapanos, P Skapinakis, MS Elisaf, ... European Journal of Cardiovascular Nursing 11 (3), 297-303, 2012	73	2012
Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose MS Kostapanos, HJ Milionis, AD Agouridis, CV Rizos, MS Elisaf International journal of clinical practice 63 (9), 1308-1313, 2009	73	2009
Statin pleiotropy against renal injury MS Kostapanos, EN Liberopoulos, MS Elisaf Journal of the CardioMetabolic Syndrome 4 (1), E4-E9, 2009	71	2009
The effects of orlistat and fenofibrate, alone or in combination, on high‐density lipoprotein subfractions and pre‐beta1‐HDL levels in obese patients with metabolic syndrome TD Filippatos, EN Liberopoulos, M Kostapanos, IF Gazi, EC Papavasiliou, ... Diabetes, Obesity and Metabolism 10 (6), 476-483, 2008	71	2008
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia MS Kostapanos, HJ Milionis, TD Filippatos, ES Nakou, ET Bairaktari, ... Clinical therapeutics 29 (7), 1403-1414, 2007	64	2007
Fenofibrate and the kidney: an overview MS Kostapanos, M Florentin, MS Elisaf European journal of clinical investigation 43 (5), 522-531, 2013	62	2013
Hemostatic factors and the metabolic syndrome M S Kostapanos, M Florentin, M S Elisaf, D P Mikhailidis Current vascular pharmacology 11 (6), 880-905, 2013	59	2013
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia MS Kostapanos, CS Derdemezis, TD Filippatos, HJ Milionis, DN Kiortsis, ... European journal of pharmacology 578 (2-3), 249-252, 2008	56	2008
Apolipoprotein B-to-A1 ratio as a predictor of acute ischemic nonembolic stroke in elderly subjects MS Kostapanos, LG Christogiannis, E Bika, ET Bairaktari, JA Goudevenos, ... Journal of Stroke and Cerebrovascular Diseases 19 (6), 497-502, 2010	55	2010

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors